Cagrilintides ~10.8% was measured at 26 weeks at 4.5 mg
Trulicity is an FDA-cleared diabetes treatment (reflecting FDA approval for its indicated use), but lawsuits examine whether some patients still experienced serious health problems and severe complications that warranted closer scrutiny
Appetite shifts, better portion control, and steadier energy are commonly reported well before the scale reflects major progress
They are new drugs - which mimic GLP-1, a natural hormone that regulates hunger - and the potential side effects from using them in the long term are only just beginning to emerge
If you have concerns, or medical condition(s), or are taking prescription medication(s), please speak to a healthcare provider before adding Nutrafol products to your routine
Key Players in the Obesity GLP-1 Market Novo Nordisk Eli Lilly and Company Amgen BoehringerIngelheim AstraZeneca Pfizer Roche Viking Therapeutics Structure Therapeutics Zealand Pharma Scope of the Report Obesity GLP-1 Market by Segments By Molecule Class: Semaglutide Tirzepatide Other GLP-1 Receptor Agonists By Route of Administration: Injectables Oral Formulations By Payer Type: Public Coverage Private Insurance and Self-Pay By Use-Case Framing: Weight Management Cardiovascular Risk Anchored By Region: North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Netherlands Rest of Europe East Asia China Japan South Korea South Asia and Pacific India Australia New Zealand Frequently Asked Questions How big is the obesity GLP-1 market in 2025
